instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Former Minister of Health Oly Ilunga was taken into custody, police said in a statement Saturday. Ilunga resigned in July to protest President Felix Tshisekedi's decision to take over the management of the response to the world's second deadliest Ebola outbreak, which is ongoing now in eastern Congo, from Ilunga. As he resigned, Ilunga deplored the lack of cooperation between him, the president and the prime minister in response to the deadly Ebola outbreak. Police said Saturday that Ilunga had been arrested less than a month ago for misdemeanor offenses involving the mishandling of funds and he was released. He has since made plans to travel to the neighboring Republic of Congo, they said, adding he was taken into custody to make sure he would not avoid legal proceedings. Congo's National Ebola Response Committee released the latest Ebola numbers Friday after a discussion in Goma by the Catholic Church and the Anglican Church about efforts to help stem the spread of Ebola in communities. A mistrust of health workers and widespread security issues still threaten the fight against the Ebola outbreak in a region where armed groups have fought for decades over the mineral-rich land. The committee reported there were 3,002 confirmed Ebola cases with 1,974 confirmed deaths. The World Health Organization said Friday they recorded 40 new cases of Ebola the lowest weekly incidence of Ebola since March 2019 but said it was unclear if this positive trend would continue.
answer:
Congo police detain ex-health minister in Ebola funds probe.

question:
According to the story, brand-name aromatase inhibitors cost between $340 and $420 a month, but the story also points out that lower-costing, generic versions are available in the U.S. It would have been useful had the story also provided cost information for the other preventive drug options, tamoxifen and raloxifene. A particular strength of this story is its presentation of data. Dr. Winer, an independent source included in the story, translates a 65% risk reduction to mean that exemestane may reduce a woman's risk of developing breast cancer from 3% to 1%. Not only does the story provide absolute risk, but it also presents the number needed to treat. According to the study authors, 26 women would need to take exemestane for five years to prevent a single case of breast cancer. It should be noted, however, that few women in the study completed five years of therapy. Since this is being used as a preventive measure in healthy women, side effects are very important and data should have been provided. The story indicates that "slightly" more women taking exemastane experienced hot flashes, fatigue, sweating, insomnia, and joint pain, compared to those taking placebo pills. It would have been helpful to note, for example, that 40% in the exemestane group experienced a hot flash versus 32% in the placebo group. Citing older research, the story indicates that that joint pain, muscle aches, problems having sex, and vaginal dryness may be more evident with a longer duration of use. The story makes it clear that the study was a large-scale, placebo-controlled, randomized trial, which enrolled over 4500 women in North America and Europe. The women included had at least one risk factor for breast cancer. It also notes that given the significant risk reduction associated with exemestane, the study was stopped after 3 years to give women in the control arm the option of taking exemestane to prevent possible breast cancers. More information regarding participants' characteristics, including age and race would have been helpful. This story did not engage in disease-mongering. In addition to including experts not affiliated with the exemestane study, the story also notes that the it was funded by the Canadian Cancer Society, the Avon Foundation, and Pfizer. In addition, the writer points out that the study lead and a few other authors have received speaking fees from Pfizer and other pharmaceutical companies that make cancer drugs. This story compares the benefits and harms of exemestane with tamoxifen; however, a mention of how these compare with raloxifene, would have been useful. The availability of aromatase inhibitors is not in question. It's clear from the story that aromatase inhibitors are currently used to prevent breast cancer recurrences. It's also clear that this is the first study evaluating its utility for preventing the first instance of breast cancer in healthy women with a higher risk of developing the disease. The story does not appear to be based on the press release.
answer:
Hormone-blocking drug reduces breast cancer risk

question:
Chazz Smith told a rally of over 80 people in the Capitol rotunda that his younger cousin had everything, yet opioids still took his life in 2016 . Authorities blamed counterfeit pills laced with fentanyl that looked like generic Vicodin. Smith said Prince's death shows the power that addiction can hold on anyone. "We've lost legends, we've lost potential legends, and that's a shame," Smith said. The rally preceded a hearing before a House health and human services committee on a bill to require manufacturers and wholesalers that sell or distribute opioids in Minnesota to pay registration fees ranging as high as $500,000 for the biggest companies. The current fee is just $235. The measure is a different approach from the "penny a pill" tax that passed the Senate last year but stalled out in the House amid industry opposition. It would raise about $20 million annually to fund prevention, treatment and education programs, and to support county child protection agencies that have been swamped by the crisis. Lt. Gov. Peggy Flanagan told the gathering that passing the bill is a priority for Democratic Gov. Tim Walz. Bill sponsors said at a news conference that the industry should pay its fair share for a crisis that it helped create. They pointed out that more than 400 people died of opioid overdoses in Minnesota in 2017, according to the Minnesota Department of Health. "In communities across the state, it appears that this opioid crisis that we're in really has no end in sight," said Rep. Liz Olson, a Duluth Democrat. "Without this swift legislative action, there indeed might not be an end. Parents have lost children, teachers have lost students, our first responders are asked to respond to impossible situations, and no other family deserves to go through this." Other leading sponsors include Rep. Dave Baker, a Republican from Willmar, and Sen. Chris Eaton, a Brooklyn Park Democrat, who have both lost children to opioid overdoses. Baker's son, Dan, 25, died in 2011 of a heroin overdose after becoming addicted to opiate pain pills for a back injury. Eaton's daughter, Ariel, was 23 when she died of a heroin overdose in 2007. "I don't want other families to go through the trauma that I did," Eaton said. Sen. Julie Rosen, a Republican from Vernon Center, said the manufacturers and distributors have been "kicking and screaming a little bit" but now tell her they want to be part of the solution. "I asked them, 'What does that look like?' and I have not received an answer," she added. "We're spending billions on an issue you helped create," Rosen said. "I don't think we're asking for a whole lot for the amount that they are shipping and manufacturing for the state of Minnesota, and the amount of deaths that we have." The Pharmaceutical Research and Manufacturers of America, also known as PhRMA, opposed last year's bill. While the trade group says it supports "an extensive set of policy recommendations ," including measures to curb overprescribing, it opposes this year's bill as well. "Unfortunately, what's being proposed taxing legitimately prescribed medicines that patients rely on for legitimate medical needs to raise revenues for the state ignores evidence-based solutions, sets a dangerous precedent and ultimately won't help patients and families," Nick McGee, the trade group's director of public affairs, said in an email to The Associated Press.
answer:
Minnesota lawmakers: Tax drug makers over opioid crisis.